Description

EFLEA (Ethyl-Fluorolysergamide) is a novel lysergamide compound that may act as a prodrug for EDMA (3,4-Ethylenedioxy-Methamphetamine). Limited reports suggest it may be inactive or have very weak effects. Its pharmacology and safety profile are essentially uncharacterized.

Community Experiences

Share a single experience — does not affect the OpenMind Score.

No reports yet — share your experience!

Log in

OpenMind Score

—

No long-term score yet — old experimental ratings are no longer shown.

No data

Long-term benefit, safety, and sustainability. Acute effect strength does not count here.

ⓘ How is the score calculated?

The score uses long-term ratings only. Each axis is scored 1–10, combined as a weighted average, and capped when critical risks are very low.

Weighted average The displayed score is directly the weighted average of the long-term axes. No hidden adjustment is applied.

Risk cap Safety caps: Very low dependence, physical/psychological safety, or recovery scores limit the maximum score.

Weights

Sustained Benefit 20%

Functional Integration 10%

Emotional Aftermath 7.5%

Physical Safety & Tolerability 12.5%

Psychological Safety 12.5%

Dependence Safety 17.5%

Recovery / Tolerance / Withdrawal 7.5%

Predictability & Control 5%

Life Burden 7.5%

Log in

Comments

Log in

No comments yet.

Please sign in to suggest edits.

Related Substances

Everything in OpenMind

Track your use, check combinations and find safer use tips – even offline.

Open Web App Google Play

EFLEA

Effect Profile

Rate acute effects

Description

Community Experiences

Weights

Long-term rating

Comments

Suggest an Edit

Everything in OpenMind